Last updated: September 7, 2026
Egrifta, the tesamorelin-based treatment for excess abdominal fat in adults with HIV-associated lipodystrophy, is a small but differentiated specialty product. Its commercial position depends on a narrow FDA-approved population, high treatment cost, limited direct competition, payer coverage, and the ability of Theratechnologies to retain prescriber and patient access.
The product has two FDA-approved versions:
| Product |
Active ingredient |
FDA approval |
Dosing |
Commercial status |
| Egrifta |
Tesamorelin for injection |
November 2010 |
2 mg daily after reconstitution |
Superseded |
| Egrifta SV |
Tesamorelin for injection |
November 2018 |
1.4 mg daily |
Current marketed version |
Egrifta SV is indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy. It is not approved for general weight loss, obesity, cosmetic use, or treatment of HIV itself. [1, 2]
What is Egrifta and how does tesamorelin work?
Tesamorelin is a synthetic analog of growth hormone-releasing factor. It stimulates the pituitary release of growth hormone, which increases insulin-like growth factor 1 and promotes reduction of visceral adipose tissue. The mechanism differs from GLP-1 drugs, which primarily act through appetite, gastric emptying, and glucose regulation pathways.
Egrifta’s commercial differentiation is its indication-specific evidence in HIV-associated visceral adiposity. The product does not have a broad obesity label, and clinical use outside the approved population creates reimbursement and regulatory risk.
What clinical benefit does Egrifta provide?
Clinical trials demonstrated reductions in visceral adipose tissue measured by imaging, with smaller or variable effects on total body weight. The FDA label states that Egrifta is not indicated for weight-loss management and that treatment should be discontinued if visceral adipose tissue reduction is not clinically meaningful. [1]
Important safety and monitoring issues include:
- Increased insulin-like growth factor 1
- Glucose intolerance and diabetes risk
- Injection-site reactions
- Arthralgia and peripheral edema
- Potential impact on malignancy risk
- Fluid retention and carpal tunnel syndrome
- Contraindication in active malignancy, pregnancy, and disruption of the hypothalamic-pituitary-gonadal axis
These requirements limit use in patients who could otherwise qualify based on body-composition concerns alone.
How large is the Egrifta market?
The addressable market is narrow but commercially persistent. It is defined by four filters:
- Adults living with HIV.
- Patients with clinically relevant lipodystrophy or excess visceral abdominal fat.
- Patients receiving antiretroviral therapy who remain symptomatic despite modern treatment.
- Patients whose insurers approve a high-cost injectable product.
The product competes for a subset of the estimated U.S. HIV population rather than the much larger obesity or metabolic-disease markets. The Centers for Disease Control and Prevention estimated that approximately 1.2 million people in the United States were living with HIV in 2022, but only a small fraction has the labeled Egrifta phenotype. [3]
Egrifta therefore has a specialty-pharmaceutical profile:
| Market factor |
Effect on Egrifta |
| Disease population |
Small and concentrated in HIV specialty care |
| Unmet need |
Persistent, because antiretroviral advances do not eliminate all lipodystrophy |
| Direct competition |
Limited within the approved indication |
| Broad obesity competition |
Very high, but GLP-1 products are not direct FDA-approved substitutes |
| Prescriber base |
Infectious-disease, HIV, and selected endocrinology specialists |
| Reimbursement |
Prior authorization and documentation requirements are common |
| Treatment duration |
Potentially chronic, creating recurring revenue if patients remain adherent |
| Administration |
Daily subcutaneous injection creates adherence friction |
| Patient support |
Important for training, benefits investigation, and persistence |
What is Egrifta’s FDA regulatory status?
Egrifta was first approved in 2010 under the FDA’s standard new drug application pathway. Egrifta SV was approved in 2018 as a new formulation with a lower daily dose and a simpler reconstitution process. The newer product was designed to improve convenience and replace the original presentation.
Why did Egrifta SV replace the original Egrifta formulation?
The original product used a 2 mg daily dose and had more demanding handling requirements. Egrifta SV uses a 1.4 mg dose and was developed to improve the injection experience and product usability.
The formulation change had commercial importance because it allowed Theratechnologies to migrate patients from the original product while preserving the tesamorelin franchise. It also created a new formulation and regulatory position, although it did not transform the product into a broad metabolic medicine.
What is the FDA exclusivity position?
The original Egrifta approval occurred in 2010. The five-year new chemical entity exclusivity period would have expired in 2015, subject to the statutory exclusivity calculation and any applicable pediatric extension. Egrifta SV was approved in 2018 and received regulatory protection associated with the supplemental formulation approval, but it did not restart five-year NCE exclusivity for tesamorelin.
The principal commercial protection is therefore the combination of formulation know-how, manufacturing controls, clinical evidence, brand recognition, reimbursement infrastructure, and any active patent claims rather than remaining NCE exclusivity.
What patents protect Egrifta?
Egrifta protection is likely to be distributed across several claim categories:
- Tesamorelin composition and analog claims
- Pharmaceutical formulations
- Lyophilized or reconstituted dosage forms
- Stability and storage characteristics
- Manufacturing and purification processes
- Methods of reducing visceral adipose tissue
- Patient-selection and treatment-regimen claims
The strongest practical protection is associated with the current Egrifta SV formulation and the manufacturing process needed to deliver a stable, consistent peptide product. Method-of-use patents may provide narrower protection because a generic or follow-on manufacturer can contest the scope of an indication or use a label that omits protected methods.
How strong is the Egrifta patent estate?
Egrifta has a moderate commercial patent position rather than a broad, high-barrier biologic estate.
Its strengths are:
- Tesamorelin is a peptide with manufacturing and characterization requirements.
- The approved indication is specific and supported by clinical data.
- Product migration to Egrifta SV creates formulation and lifecycle-management protection.
- The product has no obvious interchangeable oral substitute for the labeled use.
- Manufacturing consistency can create practical barriers beyond patent claims.
Its weaknesses are:
- The underlying active ingredient has been commercially disclosed for many years.
- Original NCE exclusivity has expired.
- The patient population is narrow, which can reduce the economic value of prolonged litigation.
- Method-of-use claims may be vulnerable to skinny-label strategies.
- Generic peptide developers can challenge formulation and process claims without copying every commercial feature.
A complete patent expiration table requires the applicable current Orange Book listings and patent-family prosecution records. Public FDA labeling confirms the approved product and formulation but does not by itself establish the full enforceable patent estate.
What is the Orange Book status of Egrifta?
Egrifta is an FDA-approved small-molecule/peptide drug product regulated through an NDA, not a monoclonal antibody biologic license application. Orange Book relevance is therefore greater than Purple Book relevance.
The commercial questions are:
- Which patents are listed against the current Egrifta SV NDA?
- Which listed patents cover the formulation rather than tesamorelin itself?
- Are any patents listed for methods of use?
- Have ANDA applicants submitted Paragraph IV certifications?
- Has Theratechnologies initiated litigation within the 45-day statutory period?
No major public Paragraph IV litigation has established a generic launch schedule for Egrifta SV through the principal public record cited here. That reduces immediate generic-entry visibility but does not eliminate future challenge risk.
When does Egrifta lose exclusivity?
Egrifta’s exclusivity loss is occurring in stages rather than on one date.
| Protection layer |
Timing |
Commercial implication |
| Original NCE exclusivity |
Approximately 2015 |
No remaining five-year NCE barrier |
| Original Egrifta formulation |
Earlier product generation |
Commercially displaced by Egrifta SV |
| Egrifta SV regulatory protection |
Began with 2018 approval |
Protected the newer formulation and approval pathway for a limited period |
| Listed patents |
Patent-specific |
Expiration depends on claim, patent term adjustment, and litigation |
| Manufacturing know-how |
Potentially indefinite if maintained as trade secret |
Practical barrier, not a substitute for patent exclusivity |
| Market exclusivity from brand position |
Ongoing but contestable |
Depends on reimbursement, adherence, and generic substitution |
A generic launch could occur before all commercial protection disappears if an applicant prevails in Paragraph IV litigation, obtains a covenant not to sue, or uses a label that avoids protected methods.
Which companies are challenging Egrifta?
No prominent generic or biosimilar challenger has publicly established a launch timetable comparable with major blockbuster products. The competitive field is more fragmented:
- Generic peptide manufacturers could pursue an ANDA or another abbreviated pathway.
- Contract manufacturers could supply a challenger with peptide-production capacity.
- HIV-focused pharmaceutical companies could compete through portfolio allocation and patient-support programs.
- GLP-1 manufacturers compete indirectly for prescriber attention and payer budgets, even though their products do not carry the Egrifta indication.
Egrifta is not exposed to conventional biosimilar substitution in the same manner as a monoclonal antibody. Tesamorelin is a synthetic peptide drug, and the relevant generic pathway is generally the ANDA framework rather than a biosimilar filing under the Public Health Service Act.
What is Egrifta’s financial trajectory?
Egrifta has developed into a recurring specialty-product revenue stream for Theratechnologies rather than a mass-market growth asset. The company’s broader HIV portfolio, including Trogarzo, has historically been central to consolidated revenue, while Egrifta contributes a smaller but strategically useful revenue base. [4, 5]
The financial trajectory has four phases:
2010 to 2016: launch and external commercialization
Egrifta entered the market with a narrowly defined indication and a specialist prescribing base. Commercial execution was initially linked to external commercialization arrangements, including EMD Serono. The product’s narrow use and administration requirements constrained rapid uptake.
2017 to 2019: rights consolidation and formulation transition
Theratechnologies increased control over Egrifta’s commercial strategy and introduced Egrifta SV in 2018. The formulation transition was important because it reduced reliance on the original presentation and created a clearer lifecycle-management platform.
2020 to 2022: access pressure and operational volatility
The COVID-19 period affected specialist visits, elective body-composition assessments, treatment starts, and pharmacy fulfillment. Egrifta also remained sensitive to insurance authorization and patient-support execution.
2023 onward: mature specialty franchise
Egrifta’s growth opportunity is primarily penetration, persistence, and improved access rather than expansion into the general obesity market. The product can generate recurring sales from chronic therapy, but the revenue ceiling remains constrained by the size of the HIV lipodystrophy population.
Theratechnologies reports consolidated revenue and product-level performance through its annual filings and earnings releases. Egrifta should be analyzed together with the company’s HIV portfolio because product-level disclosures are not always presented in a consistent, fully segmented series. [4, 5]
What drives Egrifta revenue growth?
Egrifta revenue is most sensitive to five variables:
- New patient starts from HIV specialists.
- Continuation rates after the initial treatment period.
- Prior-authorization approval rates.
- Net price after rebates and discounts.
- Migration from the original product to Egrifta SV.
The most valuable patients are those who remain on treatment over multiple years. Patient support programs can affect revenue materially because injection training, benefits verification, copay assistance, and refill coordination influence persistence.
Revenue growth is less likely to come from price increases alone. High list prices can increase payer friction and reduce access, especially when the product is used for a quality-of-life indication rather than a condition that immediately affects survival.
What generic launch risks exist for Egrifta?
A generic launch would likely occur through one of four scenarios:
| Scenario |
Timing risk |
Expected impact |
| No near-term ANDA challenge |
Low immediate risk |
Continued branded pricing and recurring revenue |
| Paragraph IV challenge |
Moderate strategic risk |
Litigation, potential settlement, and launch-date negotiation |
| Skinny-label generic |
Moderate risk |
Reduced legal exposure but possible pharmacy and payer substitution |
| Formulation or process challenge |
Longer-term risk |
Could target Egrifta SV without directly copying every use claim |
The commercial impact of a generic may be slower than for a primary-care drug because Egrifta is specialist prescribed and requires patient training. It could still be substantial if payers mandate substitution or if a generic offers materially lower net cost.
What licensing deals affect Egrifta?
Egrifta’s commercialization history included a relationship with EMD Serono. Theratechnologies later assumed a more direct role in the U.S. business and commercialized Egrifta SV. The strategic effect was to retain more control over pricing, patient services, and lifecycle management while also taking on greater commercial infrastructure costs. [4]
The franchise does not appear to depend on a large current royalty stream from a multinational partner. Its economics are therefore tied more directly to Theratechnologies’ commercial execution and manufacturing arrangements.
How does Egrifta compare with GLP-1 drugs?
| Attribute |
Egrifta |
GLP-1 therapies |
| Approved use |
HIV-associated lipodystrophy |
Diabetes and/or obesity, depending on product |
| Primary effect |
Reduction in visceral adipose tissue |
Weight loss, glucose control, metabolic effects |
| Patient population |
Narrow HIV specialty population |
Broad metabolic-disease population |
| Administration |
Daily injection |
Daily or weekly, depending on product |
| Direct substitution |
Limited |
Not FDA-approved as a substitute for Egrifta |
| Market size |
Small |
Very large |
| Reimbursement |
Specialty prior authorization |
Highly variable and increasingly restrictive |
| Competitive pressure |
Indirect |
Strong pressure on specialist budgets and patient expectations |
Egrifta’s clinical and regulatory niche protects it from direct substitution, but the popularity of GLP-1 therapies can change how clinicians and patients evaluate any injectable body-composition treatment.
What geographic markets matter for Egrifta?
The United States is the primary commercial market because Egrifta received FDA approval and Theratechnologies built its principal commercial infrastructure there. International opportunity is narrower because approval, reimbursement, and treatment guidelines vary by jurisdiction.
Geographic expansion faces three constraints:
- HIV lipodystrophy is a specialized indication.
- Pricing and reimbursement differ sharply across national systems.
- Local regulatory approval may require country-specific clinical and health-economic evidence.
The most credible international opportunities are markets with substantial treated HIV populations, specialist HIV care, and reimbursement for treatment-related body-composition complications.
Key Takeaways
- Egrifta is a niche, recurring-revenue specialty drug for HIV-associated excess abdominal fat.
- Egrifta SV replaced the original 2 mg formulation and is the current commercial product.
- The product has limited direct competition but operates in a narrow patient population.
- Original NCE exclusivity has expired; future protection depends on formulation, method-of-use, process, and manufacturing barriers.
- No major public Paragraph IV launch timetable currently defines the franchise.
- Biosimilar risk is limited because tesamorelin is a synthetic peptide drug rather than a conventional biologic marketed through the BLA pathway.
- Revenue growth depends more on patient starts, persistence, reimbursement, and support services than on expansion into general obesity.
- GLP-1 drugs are indirect commercial competitors but are not FDA-approved substitutes for Egrifta.
- Egrifta remains strategically valuable to Theratechnologies as a differentiated HIV portfolio product, although its revenue ceiling is constrained by the indication.
FAQs
Is Egrifta approved for general weight loss?
No. Egrifta is approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved for general obesity or cosmetic weight reduction. [1]
Is Egrifta a biologic drug?
Tesamorelin is a synthetic peptide regulated as an NDA drug product. Egrifta is not a monoclonal-antibody biologic and does not create the same automatic biosimilar pathway risk associated with many large-molecule biologics.
Can patients take Egrifta with GLP-1 drugs?
The FDA label does not establish Egrifta as combination therapy with GLP-1 products. Any combination would require individualized clinical judgment and consideration of glucose, growth-factor, and adverse-event risks.
How long do patients remain on Egrifta?
Treatment duration varies. Because Egrifta is intended for a chronic HIV-associated condition, continued use may generate recurring revenue when patients show benefit and maintain insurance coverage. The FDA label requires evaluation of clinical response rather than automatic indefinite treatment. [1]
What is the largest commercial risk to Egrifta?
The largest risk is not immediate biosimilar competition. It is the combination of a narrow eligible population, payer restrictions, daily injection burden, treatment discontinuation, and future generic or formulation challenges that could reduce net pricing.
References
-
U.S. Food and Drug Administration. (2023). Egrifta SV (tesamorelin) for injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2018, November 10). FDA approves new formulation of Egrifta for HIV-associated lipodystrophy. FDA.
-
Centers for Disease Control and Prevention. (2024). Estimated HIV incidence and prevalence in the United States, 2018-2022. U.S. Department of Health and Human Services.
-
Theratechnologies Inc. (2024). Annual report for the fiscal year ended November 30, 2023. Theratechnologies.
-
Theratechnologies Inc. (2024). Management discussion and analysis and financial results. Theratechnologies.
